FDA Approves Three Immunotherapy Drugs for Patients with Bladder Cancer



The FDA has approved three immunotherapy drugs—avelumab, atezolizumab, and durvalumab—for the treatment of patients with bladder cancer. All three drugs belong to a class of cancer therapies known as checkpoint inhibitors.



Source link

Comments are closed.